Daniel LaBarbera,
Associate Professor, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences,
University of Colorado Anschutz Medical Campus
Dr. LaBarbera is a tenured Associate Professor of drug discovery and medicinal chemistry at the University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences. He has 20 years of experience in the field of drug discovery and medicinal chemistry with multidisciplinary expertise in natural products, drug design, medicinal chemistry, high-throughput/high-content screening (HTS/HCS) drug discovery, 3D tumor organoid models, and pharmacology. He has a recognized research program focused on drug development targeting cancer, diabetes, and infectious diseases that has been continually funded by the U.S. NIH and the Department of Defense Congressionally Directed Medical Research Program (CDMRP), the State of Colorado, and other significant foundations grants.
Tumor Organoids and Patient Derived Tumor Organoids for HCS Drug Discovery and Personalized Medicine
Friday, 5 October 2018 at 09:00
Add to Calendar ▼2018-10-05 09:00:002018-10-05 10:00:00Europe/LondonTumor Organoids and Patient Derived Tumor Organoids for HCS Drug Discovery and Personalized Medicine3D-Culture and Organoids in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
The past decade has seen a revolution in developing 3D tissue models of organ function, anatomy, and disease. These models are referred to as organoid, organotypic, or spheroid and these terms are used interchangeably throughout the literature. Organoids are defined by their ability to mimic in vivo organ function and/or disease, they can be engineered with multiple cell types and microenvironment components, and organoids have the distinct ability to self-assemble. Like organoids, tumor organoids mimic in vivo tumor biology and recapitulate key interactions between extracellular matrix (ECM) molecules and tumor cell receptors that initiate signaling events regulating and promoting cancer. This presentation will discuss our recent work with gastrointestinal tumor organoid models of epithelial-mesenchymal transition (EMT). These models feature an innovative dual fluorescent biomarker reporter of EMT that can effectively track the forward and reverse EMT transition in live tumor organoids. We have engineered stable dual reporter SW620 cells as single uniform tumor organoids per well in 96-or-384 well plate formats, and have conducted 3D high-content screening (HCS) drug discovery of thousands of compounds. Additionally, we will discuss hit confirmation and secondary assays used to validate compounds that modulate or reverse EMT. Finally, we will discuss our most recent advances to develop patient derived tumor organoid (PDTO) models suitable for high-content analysis and HCS towards achieving the goal of personalized medicine in cancer.
Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/London3D-Culture and Organoids3D-Culture and Organoids in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-10-05 09:00:002018-10-05 10:00:00Europe/LondonTumor Organoids and Patient Derived Tumor Organoids for HCS Drug Discovery and Personalized Medicine3D-Culture and Organoids in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
